Equities analysts expect that Insmed, Inc. (NASDAQ:INSM) will report earnings of ($0.97) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Insmed’s earnings, with estimates ranging from ($1.08) to ($0.81). Insmed reported earnings per share of ($0.72) during the same quarter last year, which indicates a negative year-over-year growth rate of 34.7%. The business is scheduled to announce its next earnings results on Thursday, August 2nd.
According to Zacks, analysts expect that Insmed will report full year earnings of ($4.00) per share for the current year, with EPS estimates ranging from ($4.67) to ($3.24). For the next fiscal year, analysts forecast that the company will report earnings of ($3.03) per share, with EPS estimates ranging from ($3.97) to ($2.20). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Insmed.
Insmed (NASDAQ:INSM) last released its earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($0.89) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.96) by $0.07.
Several equities analysts have recently commented on INSM shares. Zacks Investment Research cut Insmed from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. BidaskClub cut Insmed from a “hold” rating to a “sell” rating in a research note on Tuesday, March 20th. Morgan Stanley started coverage on Insmed in a research note on Wednesday, March 21st. They set an “overweight” rating and a $39.00 target price for the company. ValuEngine upgraded Insmed from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Credit Suisse Group upgraded Insmed from a “neutral” rating to an “outperform” rating and increased their target price for the company from $27.00 to $31.00 in a research note on Monday, April 23rd. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $36.90.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Summit Trail Advisors LLC bought a new position in Insmed during the first quarter worth $250,000. WINTON GROUP Ltd bought a new position in Insmed during the first quarter worth $479,000. Xact Kapitalforvaltning AB lifted its stake in Insmed by 86.9% during the first quarter. Xact Kapitalforvaltning AB now owns 15,481 shares of the biopharmaceutical company’s stock worth $349,000 after purchasing an additional 7,200 shares during the last quarter. Nexthera Capital LP lifted its stake in Insmed by 84.1% during the first quarter. Nexthera Capital LP now owns 918,523 shares of the biopharmaceutical company’s stock worth $20,685,000 after purchasing an additional 419,602 shares during the last quarter. Finally, PointState Capital LP bought a new position in Insmed during the first quarter worth $5,090,000.
Shares of Insmed stock traded up $0.14 on Thursday, hitting $26.27. 4,689 shares of the company’s stock traded hands, compared to its average volume of 657,285. The stock has a market cap of $2.02 billion, a P/E ratio of -9.11 and a beta of 1.07. The company has a current ratio of 20.01, a quick ratio of 20.01 and a debt-to-equity ratio of 0.70. Insmed has a 52-week low of $11.49 and a 52-week high of $33.94.
Insmed Company Profile
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.
Get a free copy of the Zacks research report on Insmed (INSM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.